An Italian maker of the glass vials, syringes, cartridges, and ampoules that hold injectable medicines, along with the drug delivery devices and inspection systems used alongside them. It began in 1949 as Soffieria Stella, a small glass-blown workshop near Venice started by Giovanni Stevanato, whose name it now carries. A fun detail: the firm still builds its own high-precision glass-forming machines in-house.
Stevanato Group Q2 2026 revenue up 8% to €302.0M, divests Balda C. Brewer
Revenue increased 8% year-over-year to €302.0 million in Q2 2026, with high-value solutions representing 45% of total revenue.
Show detailsHide details
Gross profit margin rose 60 basis points to 28.7%, and adjusted EBITDA margin improved 280 basis points to 26.0%.
The company completed the divestiture of its California-based subsidiary, Balda C. Brewer, Inc., recording €12.2 million in related expenses.
Diluted EPS was €0.08, while adjusted diluted EPS was €0.14.
Full-year 2026 guidance updated: revenue expected between €1.260 billion and €1.280 billion, adjusted EBITDA between €335.0 million and €345.2 million, and adjusted diluted EPS between €0.60 and €0.62.
Stevanato Group convenes May 26, 2026 shareholders' meeting to approve FY2025 results and dividend.
Stevanato Group S.p.A. published a convening notice on April 11, 2026 for an ordinary and extraordinary shareholders' meeting to be held via teleconference on May 26, 2026 at 4:00 p.m. CEST.
Show detailsHide details
The ordinary session agenda includes approval of FY2025 financial statements, allocation of net profits and dividend distribution, appointment of the Board of Directors, compensation of directors and audit committee, appointment of external auditor for 2026-2028, and authorization for treasury share purchases.
The extraordinary session agenda includes amendments to Articles 7.6, 16, and 23 of the Company's bylaws.
The record date for voting is May 1, 2026; shareholders must submit forms by May 21, 2026.
The filing also includes exhibits such as the Sustainability Report, committee reports, and a slate of candidate directors.